DSpace Repository

Voriconazole as a first-line treatment against potentially pathogenic Acanthamoeba strains from Peru

Show simple item record

dc.contributor.author Cabello-Vílchez, A.M.
dc.contributor.author Martín-Navarro, C.M.
dc.contributor.author López-Arencibia, A.
dc.contributor.author Reyes-Batlle, M.
dc.contributor.author Sifaoui, I.
dc.contributor.author Valladares, B.
dc.contributor.author Piñero, J.E.
dc.contributor.author Lorenzo-Morales, J.
dc.date.accessioned 2020-06-10T18:12:13Z
dc.date.available 2020-06-10T18:12:13Z
dc.date.issued 2013
dc.identifier.uri https://hdl.handle.net/20.500.12866/8051
dc.description.abstract Pathogenic strains of Acanthamoeba genus are the causative agents of fatal granulomatous amoebic encephalitis and a serious sight-threatening infection of the eye known as Acanthamoeba keratitis. In a previous study, Acanthamoeba strains were isolated from nasal swabs collected from healthy individuals in Peru. In the present study, the pathogenic potential of the isolated strains was established based on temperature and osmotolerance assays as well as the secretion rate of extracellular proteases. Based on these experiments, four strains that showed the highest pathogenic potential were selected for sensitivity assays against two molecules (voriconazole and chlorhexidine) which are currently used for the treatment of Acanthamoeba infections. After performing sensitivity and activity assays, it was found that both drugs were active against the tested strains. However, voriconazole showed higher activity against the studied strains compared to chlorhexidine. Therefore, voriconazole should be established as a first-line treatment against Acanthamoeba infections at least in the studied region of Peru. en_US
dc.language.iso eng
dc.publisher Springer
dc.relation.ispartof urn:issn:1432-1955
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Peru en_US
dc.subject Humans en_US
dc.subject human en_US
dc.subject priority journal en_US
dc.subject voriconazole en_US
dc.subject article en_US
dc.subject Parasitic Sensitivity Tests en_US
dc.subject Acanthamoeba en_US
dc.subject antibiotic sensitivity en_US
dc.subject sensitivity analysis en_US
dc.subject pathogenicity en_US
dc.subject normal human en_US
dc.subject antimicrobial therapy en_US
dc.subject proteinase en_US
dc.subject nose smear en_US
dc.subject Amebiasis en_US
dc.subject Acanthamoeba castellanii en_US
dc.subject Amebicides en_US
dc.subject antiviral activity en_US
dc.subject chlorhexidine en_US
dc.subject Chlorhexidine en_US
dc.subject IC 50 en_US
dc.subject Pyrimidines en_US
dc.subject secretion rate en_US
dc.subject Triazoles en_US
dc.title Voriconazole as a first-line treatment against potentially pathogenic Acanthamoeba strains from Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1007/s00436-013-3705-8
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.07

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account